KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Construction in Progress (2023 - 2025)

AbCellera Biologics (ABCL) has disclosed Construction in Progress for 3 consecutive years, with $118.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Construction in Progress rose 27.63% year-over-year to $118.7 million, compared with a TTM value of $118.7 million through Sep 2025, up 27.63%, and an annual FY2024 reading of $103.2 million, up 13.41% over the prior year.
  • Construction in Progress was $118.7 million for Q3 2025 at AbCellera Biologics, up from $116.0 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $118.7 million in Q3 2025 and bottomed at $10.5 million in Q2 2023.
  • Average Construction in Progress over 3 years is $59.1 million, with a median of $54.3 million recorded in 2023.
  • The sharpest move saw Construction in Progress rose 13.41% in 2024, then skyrocketed 792.31% in 2025.
  • Year by year, Construction in Progress stood at $91.0 million in 2023, then grew by 13.41% to $103.2 million in 2024, then increased by 15.02% to $118.7 million in 2025.
  • Business Quant data shows Construction in Progress for ABCL at $118.7 million in Q3 2025, $116.0 million in Q2 2025, and $17.6 million in Q1 2025.